Matrix metalloproteinases (MMPs) are regulated at multiple transcriptional and post-transcriptional levels, among which receptor-mediated endocytic clearance. We previously showed that low-density lipoprotein receptor-related protein-1 (LRP-1) mediates the clearance of a complex between the zymogen form of MMP-2 (proMMP-2) and tissue inhibitor of metalloproteinases, TIMP-2, in HT1080 human fibrosarcoma cells. Here we show that, in BN16 rat yolk sac cells, proMMP-2:TIMP-2 complex is endocytosed through a distinct LRP member, megalin/LRP-2. Addition of receptor-associated protein (RAP), a natural LRP antagonist, caused accumulation of endogenous proMMP-2 and TIMP-2 in conditioned media. Incubation with RAP also inhibited membrane binding and cellular uptake of exogenous iodinated proMMP-2:TIMP-2. Moreover, antibodies against megalin/LRP-2, but not against LRP-1, inhibited binding of proMMP-2:TIMP-2 to BN16 cell surface. BIAcore analysis confirmed direct interaction between the complex and megalin/LRP-2. Conditional renal invalidation of megalin/LRP-2 in mice resulted in accumulation of proMMP-2 and TIMP-2 in their urine, highlighting the physiological relevance of the binding. We conclude that megalin/LRP-2 can efficiently mediate cell-surface binding and endocytosis of proMMP-2:TIMP-2 complex. Therefore megalin/LRP-2 can be considered as a new actor in regulation of MMP-2 activity, an enzyme crucially involved in many pathological processes.
Matrix metalloproteinases (MMPs) compose a family of Zn 2+ -dependent endoproteases that display a large variety of substrates including extracellular matrix macromolecules, cell-surface receptors, growth factors, cytokines and chemokines 1 . These proteinases play important roles in physiological processes, such as wound repair 2 and cyclic endometrial remodeling 3 , as well as in the development of various pathologies including cancer 4 .
Matrix metalloproteinases are regulated at both transcriptional and post-transcriptional levels. Mechanisms of activity regulation common to all members of the MMP family include activating cleavage of the latent proenzyme form and inhibition of the active enzyme by tissue inhibitors of metalloproteinases (TIMPs) 5 . In addition, extracellular levels of certain MMPs are regulated by selective internalization and intracellular degradation. In this regard, low-density lipoprotein receptor-related proteins (LRPs) compose a family of endocytic and signaling receptors that exert their activities on a large variety of molecules including proteolytic enzymes 6 . Particularly, LRP-1 regulates the extracellular levels of MMPs and serine-proteinases 7, 8 .
Megalin/LRP-2 shares numerous common ligands with LRP-1, notably the complexes between the plasminogen activator (PA) inhibitor type-1 (PAI-1) with either tissue-type PA (tPA) 9 , pro-urokinase-type PA (pro-uPA) or mature uPA 10, 11 . Moreover, a member of the MMP family, MMP-9 also binds to both LRP-1 and -2 12 . In addition, we previously reported that LRP-1 mediates endocytic clearance of the proMMP-2:TIMP-2 complex 13 , which represents the major form of MMP-2 in biological tissues 14 .
In the present study, we investigated the ability of megalin/LRP-2 to control extracellular levels of MMP-2 and TIMP-2 by endocytosis of the proMMP-2:TIMP-2 complex. For this purpose, we used Brown Norway rat yolk sac carcinoma cells (BN16) that express megalin/LRP-2 but not LRP-1 15, 16 . We also evaluated the physiological relevance of proMMP-2 and TIMP-2 uptake in transgenic mice undergoing renal invalidation of megalin/LRP-2 17 .
Results
The LRP competitor, RAP, causes accumulation of proMMP-2 and TIMP-2 in medium conditioned by BN16 cells. We first examined whether proMMP-2 and/or its complex with TIMP-2 could represent a new ligand for megalin/LRP-2. For this purpose, we used rat yolk sac BN16 cells that expressed megalin/ LRP-2 ( Fig. 1a ). As previously reported 16 , we did not detect LRP-1 expression by these cells. In addition, endogenous expression of both proMMP-2 and TIMP-2 could be detected by zymography ( Fig. 1b ). Incubation of BN16 cells with RAP caused accumulation of both proMMP-2 and, to a lesser extent, TIMP-2 in conditioned media ( Fig. 1b ). This indicates that a member of the LDL receptor family, all of which are sensitive to ligand binding competition by RAP 18 , mediates the uptake of proMMP-2 and TIMP-2. Since LRP-1 is absent from BN16 cells ( Fig. 1a ), megalin/LRP-2 appeared to be a good candidate for mediating this process.
ProMMP-2:TIMP-2 complex binds avidly to megalin/LRP-2.
As MMP-2 is present in biological tissues and fluids mostly in its latent pro-form complexed with its specific inhibitor, TIMP-2 14 , we generated a 125 I-radiolabelled proMMP-2:TIMP-2 complex for assessing the role of megalin/LRP-2 in the clearance of the complex by BN16 cells. A time-course study indicated that cell-surface binding of 125 I-proMMP-2:TIMP-2 approached equilibrium after 120 min of incubation at 4 °C and was competitively inhibited by RAP ( Fig. 2 ). As ) corresponds to medium conditioned by mouse calvarium, as previously reported 41 . Values under the gels indicate the fold-increase by comparison with the first non-treated sample (*). Band area and intensity were measured by using IMAGEJ image analysis software. expected, binding was equally blocked by anti-megalin/LRP-2 antibodies but not by non-immune IgG ( Fig. 3 ), suggesting a predominant role of megalin/LRP-2 in this process. As a specificity control, blocking anti-LRP-1 antibodies did not impair binding of 125 I-proMMP-2:TIMP-2 to BN16 cells.
To assess whether proMMP-2:TIMP-2 complex can directly interact with megalin/LRP-2, we performed surface plasmon resonance analysis using megalin/LRP-2 immobilized on a BIAcore sensor chip. Data in Table 1 revealed a direct and strong interaction between proMMP-2:TIMP-2 complex and megalin/LRP-2, with a K D value in the 10 −8 M range. Values are means ± S.D. of three dishes. This experiment was performed twice with similar results. Megalin/LRP-2 mediates clearance of 125 I-proMMP-2:TIMP-2 complex in BN16 cells. Once at 37 °C to allow endocytosis to proceed, cell-surface bound 125 I-proMMP-2:TIMP-2 decreased progressively over time ( Fig. 4a ). Intracellular 125 I-proMMP-2:TIMP-2 was maximal after 120 min ( Fig. 4b ). Intracellularly degraded ligand was progressively secreted back into the medium as trichloroacetic acid-soluble material and accumulated up to 240 min ( Fig. 4c ). Chloroquine treatment, which blocks lysosomal proteolysis by inhibiting endosomal acidification 19 , impaired degradation of 125 I-proMMP-2:TIMP-2, (Fig. 4b,c ), suggesting that intracellular breakdown of the complex was occurring in the lysosome. Altogether, these data indicate that megalin/LRP-2 can be an efficient receptor for endocytic clearance of the proMMP-2:TIMP-2 complex.
Renal invalidation of megalin/LRP-2 expression in mice induces elimination of proMMP-2 and TIMP-2 in urine. To determine whether megalin/LRP-2 can also mediate proMMP-2:TIMP-2 complex clearance in vivo, we used transgenic mice in which a conditional knockout of megalin expression (cKO) is induced by Wnt-4-driven Cre recombinase (Meg lox/lox ;Wnt4-Cre + mice) 17 . Megalin/LRP-2 is the major endocytic receptor for the tubular retrieval of filtered plasma proteins 20 and megalin/LRP-2 cKO results in proteinuria. We therefore compared, by direct and reverse zymography, urines of cKO mice and of their wild-type littermates (Fig. 5 ). Megalin/LRP-2 cKO resulted in a strong accumulation of both proMMP-2 and TIMP-2 in the urines, suggesting that megalin/LRP-2 mediates renal reabsorption of these proteins.
Discussion
In the present study, we show that megalin/LRP-2 acts as an endocytic receptor for proMMP-2:TIMP-2 complex. We found that RAP, an antagonist of the LDL receptor family 18 , competed with binding of proMMP-2:TIMP-2 complex onto rat BN16 epithelial cells. More specifically, anti-megalin/LRP-2 antibodies similarly inhibited binding of the complex. Moreover, megalin/LRP-2 was shown by surface plasmon resonance analysis to directly bind proMMP-2:TIMP-2, with a K D in the 10 −8 M range. Similar ranges were previously reported for the binding between megalin/LRP-2 and the proMMP-9:TIMP-1 complex 12 as well as between LRP-1 and proMMP-2:TIMP-2 13 . We further show that following cell-surface binding, proMMP-2:TIMP-2 complex is rapidly internalized by BN16 cells. We previously reported similar LRP-1-mediated endocytosis of proMMP-2:TIMP-2 in HT1080 cells. However, this involved initial RAP-insensitive binding of the complex to an unknown neighboring binding site at the plasma membrane 13 , whereas we report here a simple RAP-sensitive uptake mediated by megalin/LRP-2. Whether other similar complexes, such as proMMP-2:TIMP-4 21 , are also able to be internalized by LRP-1 or megalin/LRP-2-mediated endocytosis remains to be determined.
Although our data clearly show that megalin/LRP-2 directly binds proMMP-2:TIMP-2, it is possible that other membrane proteins acting as co-receptors, such as cubilin, contribute to internalization of the complex. Indeed, the megalin/cubilin receptor complex is important for physiological retrieval of various proteins and vitamins, as illustrated by studies in animal models such as the Meg lox/lox ;Wnt4-Cre + mice we used 17, 22, 23 . Deficient reabsorption of proMMP-2 and TIMP-2 by kidney-specific conditional KO mice underlines the major contribution of megalin/LRP-2. Since cubilin is still expressed in the kidney of the these cKO mice 17 , further studies are needed to clarify whether additional cubilin binding of proMMP-2 and TIMP-2 could occur in vivo prior to megalin-mediated internalization, as reported for albumin 24 .
Abrogation of complex degradation upon chloroquine addition 19 strongly suggests that proMMP-2 and TIMP-2 are intracellularly degraded in a lysosomal-dependent process as previously evidenced for MMP-9 12 . However, additional studies would be interesting to analyze in more details the intracellular outcome of the ligands.
Our in vivo study highlights physiological relevance of megalin/LRP-2-mediated proMMP-2 and TIMP-2 uptake. In contrast, increased urinary concentration of proMMP-2 and/or TIMP-2 was measured in pathological situations involving kidney deficiency such as renal carcinoma [25] [26] [27] and type 1 diabetic nephropathy 28 , suggesting reduced renal proMMP-2 and TIMP-2 reabsorption. Interestingly, it was recently reported that accumulation of MMP-7 in urine could play a role in the pathogenesis of kidney fibrosis 29 , suggesting that clearance of urinary MMPs may be important to preserve renal function. In addition, megalin/LRP-2 has been localized at the surface of type II pneumocytes of the lung alveoli 30 where megalin/LRP-2-mediated endocytosis could thus represent a new mechanism for regulating levels of MMP-2 and MMP-9. Of note, these MMPs are largely increased in the airspace of patients with acute lung injury or acute respiratory distress syndrome 31 as well as in idiopathic interstitial pneumonias 32 . Moreover, several MMPs and TIMPs, including MMP-2, MMP-9 and TIMP-2, are present in the semen 33, 34 . Furthermore, MMPs are found in the uterine fluid of buffalo 35 and TIMP-4, an inhibitor of MMP-2 and MMP-9, is released into the uterine fluid 36 . Interestingly, megalin/LRP-2 is localized at the apical surface of the glands and surface epithelium in human endometrium 37 and consequently is in contact of both semen and uterine fluids. Therefore, megalin/LRP-2 could protect the endometrium by regulating MMP activities from these fluids.
In conclusion, our study shows that megalin/LRP-2 directly binds the proMMP-2:TIMP-2 complex and is involved in its endocytic uptake, with potential physiological roles such as in the renal clearance.
Materials and Methods
Reagents. Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), and other cell culture reagents were purchased from Invitrogen (Thermo Fischer Scientific, Erembodegem, Belgium). Na 125 I and Iodogen ® pre-coated tubes were from PerkinElmer Life Sciences and Pierce, respectively (both distributed by Thermo Fisher Scientific). Chloroquine was obtained from Sigma-Aldrich (Bornem, Belgium). Kaleidoscope SDS-PAGE molecular weight standards were from Bio-Rad Laboratories (Nazareth Eke, Belgium) and
Himark ™ prestained high-molecular-weight protein standard from Invitrogen. Pronase ® , a mixture of proteinases isolated from the extracellular fluid of Streptomyces griseus, was from Roche Applied Science (Sigma-Aldrich). Proteins and antibodies. The proMMP-2:TIMP-2 complex was purchased from Enzo Life Sciences (Brussels, Belgium). Receptor-associated protein (RAP) was prepared as previously reported 38 . Polyclonal sheep antibodies anti-rat megalin/LRP-2 were a generous gift from Dr. R. Kozyraki (INSERM UMR S968, Paris, France). Monoclonal antibody anti-human LRP-1 85-kDa β-chain (mouse IgG2, clone 5A6) was from Oncogene (Calbiochem, San Diego, CA). Monoclonal antibody anti-glyceraldehyde phosphate dehydrogenase (GAPDH) (mouse IgG1, clone 6C5) was from Merck Millipore (Darmstadt, Germany). Blocking polyclonal rabbit antibodies anti-megalin/LRP-2 and anti-LRP-1 were from Biorbyt Ltd (Cambridge, United Kingdom) and Santa Cruz Biotechnology (Heidelberg, Germany), respectively. Non-immune rabbit IgGs, used as negative controls, were from Ancell (Bayport, MN). The specificity of anti-megalin/LRP-2 antibodies was assessed by western blotting using kidney homogenates from wild-type and megalin/LRP-2 cKO mice ( Supplementary Fig. 1 ).
Cell culture and RAP treatment. Brown Norway rat yolk sac carcinoma cells (BN16) were grown in DMEM supplemented with 10% (v/v) FCS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, and 25 mM HEPES buffer at 37 °C in a humid atmosphere (5% CO 2 and 95% air). In experiments involving RAP treatment, subconfluent cells were cultured in the absence or presence of 1 μM recombinant RAP for 24 h in serum-free medium.
Animal model. Megalin/LRP-2-deficient mice were generated using a conditional Cre-loxP system (Meg lox/lox ; Wnt4-Cre + mice), as previously described 17 Protein assay. Protein content was measured using the bicinchoninic acid microassay 39 , with bovine serum albumin as a standard.
Western blotting. Western blotting was performed as previously described 13 using 4-15% pre-cast gradient polyacrylamide gels. Cell extracts were normalized to protein content (50 μg/lane). Membranes were incubated overnight at 4 °C with primary antibodies diluted 1:1,000 (LRP-1 and -2) or 1:30,000 (GAPDH) in Tris-buffered saline (TBS: 50 mM Tris-HCl, 150 mM NaCl, pH 7.5) containing 0.1% Tween-20 and 5% dry milk powder. Immunoreactive bands were visualized using enzymatic chemiluminescence (Luminata Classico Western HRP substrate, Merck Millipore).
Direct and reverse gelatin zymography. Samples of medium conditioned during twenty-four hours
were normalized with respect to protein content, diluted in non-reducing 2% (w/v) SDS sample buffer and loaded onto 10% (for direct zymography) or 15% (for reverse zymography) polyacrylamide SDS gels containing 0.1% (w/v) gelatin. After electrophoresis, gels were washed at room temperature for 2 × 30 min in 2.5% (v/v) Triton X-100 to remove SDS and incubated at 37 °C for 16 h in reaction buffer (5 mM CaCl 2 , 1 µM ZnCl 2 , 0.2 mg/ml NaN 3 , 1% (v/v) Triton X-100 in 50 mM Tris-HCl buffer, pH 7.5). For reverse zymography, the reaction buffer was supplemented with 5% (v/v) medium conditioned by cultured mouse calvarium and treated with 0.4 mM 4-aminophenylmercuric acetate for 2 h at 25 °C to activate latent MMPs 37 , before incubation. After incubation, gels were stained for 30 min with 0.1% (w/v) G-250 Coomassie Blue in 45% (v/v) methanol, 10% (v/v) glacial acetic acid, and destained in the same solution without dye. Reverse zymography revealed inhibitory activity that appeared as dark zones against a clear background.
Surface plasmon resonance analysis. The interaction of proMMP-2:TIMP-2 complex with megalin/ LRP-2 was studied using a BIAcore 3000 instrument (BIAcore, Sweden). A CM5 sensor chip was activated with a 1:1 mixture of 0.2 M N-ethyl-N′-(3-dimethylaminopropyl)carbodiimide and 0.05 M N-hydroxysuccimide in water according to the manufacturer. Human megalin/LRP-2 was immobilized at 10 µg/ml in 10 mM sodium acetate, pH 4.0 at a density of 25 fmol/mm 2 . Remaining binding sites were blocked with 1 M ethanolamine, pH 8.5. A control flowcell was made by performing the activation and blocking procedure only. Ligands were diluted in the running buffer (100 mM Tris-HCl pH 7.4, 100 mM NaCl, 10 mM CaCl 2 supplemented with 0.005% surfactant P20) and analyzed at concentrations from 10 to 250 nM. After each analysis cycle, sensor chips were regenerated using 1.6 M glycine-HCl buffer, pH 3.0. The BIAcore response, which is expressed in relative response units (RU), is the difference in response between megalin/LRP-2 and control flowcells. Kinetic parameters were determined by BIAevaluation 4.1 software using a Langmuir 1:1 binding model and simultaneous fitting of all sensorgrams.
Radioiodination. ProMMP-2:TIMP-2 complex was labeled with 125 I using Iodogen ® according to manufacturer's recommendations. Specific activities ranged from 10 to 15 μCi/μg of complex. Trichloroacetic acid-precipitable radioactivity of used radioligands was always >97%.
Radioligand binding assay. BN16 cells (5 × 10 5 ) were plated onto 35-mm dishes and cultured to confluency, then washed twice with assay medium (DMEM containing 0.1% bovine serum albumin) and adapted to this medium at 4 °C for 1 h. Cells were then incubated or not with 1 μM RAP, 100 μg/ml polyclonal rabbit anti-megalin/LRP-2 or anti-LRP-1 antibodies or non-immune IgGs in assay medium at 4 °C for 30 min, prior to addition of 10 nM 125 I-proMMP-2:TIMP-2 complex for 2 h. After careful rinsing (nine times with cold PBS, on ice), cells were surface-digested with 0.1% (w/v) pronase ® in DMEM at 4 °C to degrade surface-bound ligands and cause cell detachment. After cell collection by centrifugation, radioactivity released in supernatant (pronase ® -sensitive), measured by γ−counting, was defined as surface-bound ligand. Binding of 125 I-proMMP-2:TIMP-2 complex to plastic dishes without cells did not exceed 8% of total bound radioactivity.
Endocytosis and degradation assays. Cells adapted to 4 °C were incubated with 10 nM 125 I-proMMP-2:TIMP-2 complex in assay medium at 4 °C for 2 h, in the absence or presence of 1 μM RAP. After binding, cells were carefully rinsed nine times with cold PBS and further cultured in assay medium pre-warmed at 37 °C for the indicated times. To distinguish surface-binding from intracellular accumulation, cells were washed twice with cold PBS, and surface-digested with pronase ® as above. Radioactivity associated with pelleted cells (pronase ® -resistant) was defined as internalized ligand. After precipitation by 10% (w/v) trichloroacetic acid and centrifugation of the conditioned medium collected before pronase ® treatment, radioactivity in the supernatant was taken to indicate the amount of degraded 125 I-ligand. To inhibit lysosomal activity, 100 μM chloroquine was added to some cultures 2 h before radioligand binding. Internalization and degradation were then studied as above after 2 h at 37 °C, in the continued presence of chloroquine.
Statistical analysis. Statistical significance was tested using Student's t test for comparisons between cell culture conditions. Differences were considered as statistically significant at p < 0.05.
